Rotigotine

Nonergot Dopamine Agonist — NERVOUS SYSTEM

Key facts

Rotigotine is an ofp drug in the Nonergot Dopamine Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Dopamine Agonists. DrugCentral lists 7 molecular targets, including DRD2, DRD3 and DRD2. Recorded indications include Parkinson's disease and Restless legs.

• Approval status: ofp (first approved 2007 by the FDA).
• Drug class: Nonergot Dopamine Agonist.
• Mechanism of action: Dopamine Agonists.
• Molecular targets: DRD2, DRD3, DRD2 and DRD4 (7 listed in DrugCentral).
• Indications: Parkinson's disease and Restless legs.
• ATC code: N04BC09 (Dopamine agonists).
• Molecular formula: C19H25NOS; molecular weight 315.48 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Parkinson's disease
• Restless legs

Contraindications (11)

• Acute nephropathy
• Body fluid retention
• Breastfeeding (mother)
• Chronic heart failure
• Drowsy
• Dyskinesia
• Hypertensive disorder
• Magnetic resonance imaging
• Orthostatic hypotension
• Peripheral edema
• Syncope

Mechanism & targets

• Mechanism of action (MoA): Dopamine Agonists
• Established pharmacologic class: Nonergot Dopamine Agonist

Molecular targets (7)

Target	Gene	Action	Activity
D(2) dopamine receptor	DRD2	agonist	Ki 10.22
D(3) dopamine receptor	DRD3	agonist	Ki 8.40
D(2) dopamine receptor	DRD2	unknown	Ki 7.82
D(4) dopamine receptor	DRD4	agonist	Ki 7.26
D(1A) dopamine receptor	DRD1	unknown	Ki 6.30
D(1B) dopamine receptor	DRD5	agonist	Ki 6.00
D(1A) dopamine receptor	DRD1	agonist	Ki 5.60

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2007-05-09	FDA	—	UCB INC

ATC classification

ATC code	Therapeutic hierarchy
N04BC09	NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Dopamine agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Product adhesion issue	2510.4
Dyskinesia	730.9
On and off phenomenon	705.0
Hallucination	540.1
Stoma site discharge	342.6
Freezing phenomenon	338.1
Hallucination, visual	262.0
Application site pruritus	258.8
Stoma site erythema	255.9
Application site erythema	254.4
Impulse-control disorder	245.6
Application site reaction	241.3

Chemical structure

• Molecular formula: C₁₉H₂₅NOS
• Molecular weight: 315.48 g/mol
• CAS number: 99755-59-6
• InChIKey: KFQYTPMOWPVWEJ-INIZCTEOSA-N
• PubChem CID: 59227

CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Rotigotine used for?

DrugCentral lists the following indications for Rotigotine: Parkinson's disease and Restless legs.

How does Rotigotine work?

Rotigotine is classified as Dopamine Agonists; its molecular targets in DrugCentral include DRD2 (agonist), DRD3 (agonist), DRD2 and DRD4 (agonist).

When was Rotigotine first approved?

Rotigotine was first approved by the FDA in 2007.

What drug class does Rotigotine belong to?

Rotigotine is in the Nonergot Dopamine Agonist class.

What is the chemical formula of Rotigotine?

Rotigotine has the molecular formula C19H25NOS and a molecular weight of 315.48 g/mol.

Sources

• DrugCentral drug card 2407 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1303 — compound record and bioactivity
• PubChem CID 59227 — chemical identifiers
• DrugBank DB05271 — drug record
• FDA UNII 87T4T8BO2E — substance identity
• DailyMed: FDA labels for Rotigotine — current prescribing information (label search)
• UniProt P14416 (DRD2) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt P21917 (DRD4) — target protein
• UniProt P21918 (DRD5) — target protein
• UniProt P21728 (DRD1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.